Scientific Opinion on the substantiation of a health claim related to beta-galactosidase from Streptococcus thermophilus and reduction of gastrointestinal discomfort pursuant to Article 14 of Regulation (EC) No 1924/2006

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)

doi:10.2903/j.efsa.2014.3841

Scientific Opinion on the substantiation of a health claim related to beta-galactosidase from Streptococcus thermophilus and reduction of gastrointestinal discomfort pursuant to Article 14 of Regulation (EC) No 1924/2006

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)

Obesity Research

1 Citation (Scopus)

Abstract

Following an application from Specialised Nutrition Europe (formerly IDACE), submitted for authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to beta-galactosidase from Streptococcus thermophilus and reduction of gastrointestinal discomfort. According to the applicant, the food constituent which is the subject of the claim is beta-galactosidase from Streptococcus thermophilus. Streptococcus thermophilus is added to infant formulae in the production process for fermentation purposes and the live organisms are inactivated after the fermentation process. The Panel considers that the food constituent, beta-galactosidase from Streptococcus thermophilus, under the conditions of use proposed by the applicant, is sufficiently characterised. The claimed effect proposed by the applicant is “reduction of gastro-intestinal discomfort”. The target population proposed by the applicant is infants and young children. The Panel considers that reduction of gastrointestinal discomfort is a beneficial physiological effect. No human studies from which conclusions could be drawn for the scientific substantiation of the claim were provided by the applicant. The Panel concludes that a cause and effect relationship has not been established between the consumption of beta-galactosidase which is produced by Streptococcus thermophilus (subsequently inactivated) during fermentation of an infant formula and reduction of gastrointestinal discomfort.

Original language	English
Article number	3841
Journal	E F S A Journal
Volume	12
Issue number	10
Number of pages	8
ISSN	1831-4732
DOIs	https://doi.org/10.2903/j.efsa.2014.3841
Publication status	Published - 1 Oct 2014

Keywords

Faculty of Science
Beta-galactosidase
Lactase
Streptococcus thermophilus
Gastrointestinal discomfor
Infants
Children

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2903/j.efsa.2014.3841Licence: Unspecified

Fingerprint

Dive into the research topics of 'Scientific Opinion on the substantiation of a health claim related to beta-galactosidase from Streptococcus thermophilus and reduction of gastrointestinal discomfort pursuant to Article 14 of Regulation (EC) No 1924/2006'. Together they form a unique fingerprint.

Cite this

Scientific Opinion on the substantiation of a health claim related to beta-galactosidase from Streptococcus thermophilus and reduction of gastrointestinal discomfort pursuant to Article 14 of Regulation (EC) No 1924/2006. / EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA).

In: E F S A Journal, Vol. 12, No. 10, 3841, 01.10.2014.

Research output: Contribution to journal › Journal article › Commissioned › peer-review

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2014, 'Scientific Opinion on the substantiation of a health claim related to beta-galactosidase from Streptococcus thermophilus and reduction of gastrointestinal discomfort pursuant to Article 14 of Regulation (EC) No 1924/2006', E F S A Journal, vol. 12, no. 10, 3841. https://doi.org/10.2903/j.efsa.2014.3841

@article{a06ccba2218a41c797bb361568408f9e,

title = "Scientific Opinion on the substantiation of a health claim related to beta-galactosidase from Streptococcus thermophilus and reduction of gastrointestinal discomfort pursuant to Article 14 of Regulation (EC) No 1924/2006",

abstract = "Following an application from Specialised Nutrition Europe (formerly IDACE), submitted for authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to beta-galactosidase from Streptococcus thermophilus and reduction of gastrointestinal discomfort. According to the applicant, the food constituent which is the subject of the claim is beta-galactosidase from Streptococcus thermophilus. Streptococcus thermophilus is added to infant formulae in the production process for fermentation purposes and the live organisms are inactivated after the fermentation process. The Panel considers that the food constituent, beta-galactosidase from Streptococcus thermophilus, under the conditions of use proposed by the applicant, is sufficiently characterised. The claimed effect proposed by the applicant is “reduction of gastro-intestinal discomfort”. The target population proposed by the applicant is infants and young children. The Panel considers that reduction of gastrointestinal discomfort is a beneficial physiological effect. No human studies from which conclusions could be drawn for the scientific substantiation of the claim were provided by the applicant. The Panel concludes that a cause and effect relationship has not been established between the consumption of beta-galactosidase which is produced by Streptococcus thermophilus (subsequently inactivated) during fermentation of an infant formula and reduction of gastrointestinal discomfort.",

keywords = "Faculty of Science, Beta-galactosidase, Lactase, Streptococcus thermophilus, Gastrointestinal discomfor, Infants, Children",

author = "Inge Tetens and Sj{\"o}din, {Anders Mikael} and {EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)}",

year = "2014",

month = oct,

day = "1",

doi = "10.2903/j.efsa.2014.3841",

language = "English",

volume = "12",

journal = "E F S A Journal",

issn = "1831-4732",

publisher = "European Food Safety Authority (E F S A)",

number = "10",

}

TY - JOUR

T1 - Scientific Opinion on the substantiation of a health claim related to beta-galactosidase from Streptococcus thermophilus and reduction of gastrointestinal discomfort pursuant to Article 14 of Regulation (EC) No 1924/2006

AU - Tetens, Inge

AU - Sjödin, Anders Mikael

AU - EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Following an application from Specialised Nutrition Europe (formerly IDACE), submitted for authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to beta-galactosidase from Streptococcus thermophilus and reduction of gastrointestinal discomfort. According to the applicant, the food constituent which is the subject of the claim is beta-galactosidase from Streptococcus thermophilus. Streptococcus thermophilus is added to infant formulae in the production process for fermentation purposes and the live organisms are inactivated after the fermentation process. The Panel considers that the food constituent, beta-galactosidase from Streptococcus thermophilus, under the conditions of use proposed by the applicant, is sufficiently characterised. The claimed effect proposed by the applicant is “reduction of gastro-intestinal discomfort”. The target population proposed by the applicant is infants and young children. The Panel considers that reduction of gastrointestinal discomfort is a beneficial physiological effect. No human studies from which conclusions could be drawn for the scientific substantiation of the claim were provided by the applicant. The Panel concludes that a cause and effect relationship has not been established between the consumption of beta-galactosidase which is produced by Streptococcus thermophilus (subsequently inactivated) during fermentation of an infant formula and reduction of gastrointestinal discomfort.

AB - Following an application from Specialised Nutrition Europe (formerly IDACE), submitted for authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to beta-galactosidase from Streptococcus thermophilus and reduction of gastrointestinal discomfort. According to the applicant, the food constituent which is the subject of the claim is beta-galactosidase from Streptococcus thermophilus. Streptococcus thermophilus is added to infant formulae in the production process for fermentation purposes and the live organisms are inactivated after the fermentation process. The Panel considers that the food constituent, beta-galactosidase from Streptococcus thermophilus, under the conditions of use proposed by the applicant, is sufficiently characterised. The claimed effect proposed by the applicant is “reduction of gastro-intestinal discomfort”. The target population proposed by the applicant is infants and young children. The Panel considers that reduction of gastrointestinal discomfort is a beneficial physiological effect. No human studies from which conclusions could be drawn for the scientific substantiation of the claim were provided by the applicant. The Panel concludes that a cause and effect relationship has not been established between the consumption of beta-galactosidase which is produced by Streptococcus thermophilus (subsequently inactivated) during fermentation of an infant formula and reduction of gastrointestinal discomfort.

KW - Faculty of Science

KW - Beta-galactosidase

KW - Lactase

KW - Streptococcus thermophilus

KW - Gastrointestinal discomfor

KW - Infants

KW - Children

U2 - 10.2903/j.efsa.2014.3841

DO - 10.2903/j.efsa.2014.3841

M3 - Journal article

SN - 1831-4732

VL - 12

JO - E F S A Journal

JF - E F S A Journal

IS - 10

M1 - 3841

ER -